KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Net Margin (2019 - 2025)

Historic Net Margin for Esperion Therapeutics (ESPR) over the last 7 years, with Q3 2025 value amounting to 36.66%.

  • Esperion Therapeutics' Net Margin rose 235900.0% to 36.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 35.47%, marking a year-over-year decrease of 214500.0%. This contributed to the annual value of 1.46% for FY2024, which is 1829600.0% up from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' Net Margin is 36.66%, which was up 235900.0% from 16.25% recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Net Margin ranged from a high of 42.29% in Q1 2024 and a low of 1140.0% during Q1 2021
  • For the 5-year period, Esperion Therapeutics' Net Margin averaged around 230.12%, with its median value being 178.06% (2023).
  • In the last 5 years, Esperion Therapeutics' Net Margin skyrocketed by 31326700bps in 2021 and then plummeted by -2462800bps in 2022.
  • Over the past 5 years, Esperion Therapeutics' Net Margin (Quarter) stood at 448.4% in 2021, then skyrocketed by 33bps to 302.06% in 2022, then surged by 41bps to 178.06% in 2023, then skyrocketed by 83bps to 30.16% in 2024, then fell by -22bps to 36.66% in 2025.
  • Its Net Margin was 36.66% in Q3 2025, compared to 16.25% in Q2 2025 and 63.89% in Q1 2025.